GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » Cyclically Adjusted FCF per Share

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Cyclically Adjusted FCF per Share : $0.00 (As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Innovus Pharmaceuticals's adjusted free cash flow per share for the three months ended in Sep. 2019 was $-0.188. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2019.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-04-28), Innovus Pharmaceuticals's current stock price is $20.82. Innovus Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2019 was $0.00. Innovus Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Innovus Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Innovus Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Innovus Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Innovus Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovus Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Innovus Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovus Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innovus Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Innovus Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Innovus Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Innovus Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2019 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=-0.188/108.3294*108.3294
=-0.188

Current CPI (Sep. 2019) = 108.3294.

Innovus Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200912 0.000 91.111 0.000
201003 -0.077 91.821 -0.091
201006 -0.923 91.962 -1.087
201009 -0.231 92.162 -0.272
201012 -0.071 92.474 -0.083
201103 -1.143 94.283 -1.313
201106 -7.214 95.235 -8.206
201109 -6.231 95.727 -7.051
201112 -0.667 95.213 -0.759
201203 -4.077 96.783 -4.563
201206 -0.511 96.819 -0.572
201209 -0.468 97.633 -0.519
201212 -0.256 96.871 -0.286
201303 -0.769 98.209 -0.848
201306 -1.142 98.518 -1.256
201309 -1.265 98.790 -1.387
201312 -0.718 98.326 -0.791
201403 -1.349 99.695 -1.466
201406 -1.079 100.560 -1.162
201409 -1.241 100.428 -1.339
201412 0.209 99.070 0.229
201503 -0.306 99.621 -0.333
201506 -0.103 100.684 -0.111
201509 -1.253 100.392 -1.352
201512 -0.441 99.792 -0.479
201603 -0.172 100.470 -0.185
201606 0.436 101.688 0.464
201609 -0.996 101.861 -1.059
201612 -0.938 101.863 -0.998
201703 -0.387 102.862 -0.408
201706 -0.315 103.349 -0.330
201709 -0.376 104.136 -0.391
201712 -0.510 104.011 -0.531
201803 -0.456 105.290 -0.469
201806 -1.426 106.317 -1.453
201809 -1.060 106.507 -1.078
201812 -0.274 105.998 -0.280
201903 -0.387 107.251 -0.391
201906 -0.161 108.070 -0.161
201909 -0.188 108.329 -0.188

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Innovus Pharmaceuticals  (OTCPK:INNV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Innovus Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
8845 Rehco Road, San Diego, CA, USA, 92121
Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.
Executives
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu director
Henry Jemil Esber director 38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz officer: EVP, CORPORATE DEVELOPMENT 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn officer: VP, CFO 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj director, officer: CHIEF EXECUTIVE OFFICER C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman officer: Chief Financial Officer ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown officer: See remarks 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew director 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness director, officer: Secretary 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack director, 10 percent owner, officer: President & CEO 175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111